Recommended Birth Control Pill Regimen for PCOS

Benefits of COCs in PCOS

For patients with Polycystic Ovary Syndrome (PCOS), a combined oral contraceptive (COC) provides good cycle control and regulates menstrual patterns, as recommended by the American Academy of Pediatrics and the American Academy of Family Physicians 1, 2
Long-term use (>3 years) of COCs provides significant protection against endometrial and ovarian cancers, according to the American Academy of Pediatrics 1

The American Academy of Pediatrics and the American Academy of Family Physicians recommend a monophasic COC containing 30-35 μg ethinyl estradiol with drospirenone as first-line hormonal therapy for PCOS patients 1, 2
COCs containing 30-35 μg ethinyl estradiol with levonorgestrel or norgestimate are alternative options, as suggested by the American Academy of Pediatrics 1

The standard 28-day pack (21-24 hormone pills and 4-7 placebo pills) is recommended, according to the American Academy of Pediatrics 1
Extended or continuous cycles may be considered for patients with severe symptoms, as recommended by the American Academy of Pediatrics 1
Eliminating the hormone-free interval optimizes ovarian suppression, potentially increasing contraceptive effectiveness, according to the American Academy of Pediatrics 1

The American Academy of Family Physicians recommends monitoring metabolic parameters in PCOS patients with pre-existing insulin resistance 2
No evidence suggests increased cardiovascular events with COC use in PCOS patients compared to the general population, according to the American Academy of Family Physicians 2

The American Academy of Family Physicians suggests combining COCs with weight reduction programs and insulin-sensitizing agents like metformin for patients with significant metabolic concerns 2, 3

The American Academy of Pediatrics recommends assessing for contraindications to COC use before prescribing, including history of VTE, migraine with aura, etc. 1, 4
The baseline risk of venous thromboembolism in young women is approximately 1 per 10,000 woman-years, which increases to 3-4 per 10,000 woman-years with COC use, according to the American Academy of Pediatrics 4
The American Academy of Pediatrics advises patients about proper pill-taking and what to do if pills are missed 1

The American Academy of Family Physicians recommends monitoring for any adverse effects or changes in metabolic parameters after 3-6 months of therapy 2
The American Academy of Pediatrics suggests considering adjusting the formulation if side effects are problematic or if clinical response is inadequate 1

The American Academy of Pediatrics recommends that women with PCOS who are not attempting to conceive should undergo a pre-treatment risk assessment, including documentation of age and smoking status, as COCs are contraindicated if age ≥35 years and smoking 5
The American Academy of Pediatrics also recommends assessing blood pressure, as COCs are contraindicated if systolic ≥160 or diastolic ≥100 mm Hg 5
The American Academy of Pediatrics advises against prescribing COCs to patients with migraine with aura, as this is an absolute contraindication due to stroke risk 5

The use of COCs increases the risk of venous thromboembolism (VTE) to 3-4 per 10,000 woman-years, compared to a baseline risk of 1 per 10,000 woman-years in reproductive-age women 5
The risk of VTE varies by progestin type, with drospirenone having a slightly higher risk than levonorgestrel, though the absolute risk remains low 5

The American Academy of Pediatrics recommends against requiring a pelvic examination before prescribing COCs, as it is unnecessary for determining eligibility 5
The American Academy of Pediatrics advises against withholding COCs from adolescents or women <35 years who smoke, as smoking is not a contraindication in this age group 5
Patients should be informed that transient side effects, such as irregular bleeding, headache, and nausea, are common in the first 1-3 months of COC use 5
The American Academy of Pediatrics recommends prescribing up to 1 year of COCs at a time to improve adherence, and scheduling a follow-up visit at 1-3 months to address adverse effects or adherence issues 5